NIH Holds Secret Session on New Drug Contracts
Published Date: 4/22/2025
Notice
Summary
The National Center for Advancing Translational Sciences is holding a private meeting on May 14-15, 2025, to review secret contract proposals about developing new drug products. This meeting affects companies and researchers involved in drug development and keeps sensitive info safe. No public money changes are announced, but the decisions could impact future drug research funding.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10310 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting
The National Institute on Deafness and Other Communication Disorders is holding a private virtual meeting on July 20, 2026, to review grant applications. This meeting affects researchers seeking funding for projects related to hearing and communication disorders. No public access is allowed to protect sensitive information, and the decisions could impact future research funding.
2026-10231 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings on June 25, 2026, to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants should note the date, as these reviews impact who gets money for their work.
2026-10175 — Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a private virtual meeting on June 9, 2026, to review grant applications about infectious diseases and immunology. This closed session protects sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as this review impacts funding decisions.
2026-09947 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting health science projects. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10022 — Submission for OMB Review; 30-Day Comment Request; Early Career Reviewer Program Online Application and Vetting System (Center for Scientific Review)
The NIH wants your thoughts on their Early Career Reviewer Program’s new online application and review system. This affects early career scientists applying to review research, making the process smoother and digital. You’ve got 30 days to share your feedback—no cost changes, just a smarter way to apply!
2026-10021 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate grant applications related to health and cancer research. These meetings are private to protect sensitive information and personal privacy. Researchers applying for grants and NIH staff are the main players, with no direct cost changes announced but important deadlines to keep in mind.
Previous / Next Documents
Previous: 2025-06878 — Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform
The National Cancer Institute is planning to give Sangam Lifesciences an exclusive patent license for a cool new drug delivery technology that targets the brain and lymph system based on size. This means Sangam gets special rights to develop and sell this invention, which could speed up better treatments. If you’re in biotech or healthcare, keep an eye out—this deal could shake things up soon!
Next: 2025-06882 — Svetlana Burtman, N.P.; Decision and Order
Svetlana Burtman, a nurse practitioner in Arizona, had her DEA registration suspended and is facing revocation because she broke important rules about handling controlled substances. The government found she gave out drugs from an unregistered location and didn’t keep proper records, which could risk public safety. This decision means she can’t legally dispense these drugs anymore, and her new clinic’s registration was also denied.